Merck to forge ahead with CETP-inhibiting cholesterol med

An independent data-monitoring panel recommended that Merck & Co. ($MRK) continue studying its cholesterol-fighting CETP inhibitor, anacetrapib. The drugmaker had added a futility analysis to the study, dubbed REVEAL, after rival drugmaker Eli Lilly & Co. ($LLY) canned development of its CETP drug evacetrapib. Pfizer ($PFE) and Roche ($RHHBY) had previously given up on their own CETP meds. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.